Immune reactivation by cell-free fetal DNA in healthy pregnancies re-purposed to target tumors: Novel checkpoint inhibition in cancer therapeutics

Frontiers in Immunology

Volumn 6, Issue AUG, 2015, Pages

  Enninga, Elizabeth Ann L ^a   Nevala, Wendy K ^a   Holtan, Shernan G ^b   Markovic, Svetomir N ^a  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Cell free fetal DNA; Circulating tumor DNA; Immunotherapy; Inflammation; Toll like receptors

Indexed keywords

BIOLOGICAL MARKER; CANCER ANTIBODY; CELL FREE FETAL DNA; CHIMERIC ANTIGEN RECEPTOR; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DNA; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MONOCLONAL ANTIBODY; PROGRAMMED DEATH 1 LIGAND 1; TOLL LIKE RECEPTOR; UNCLASSIFIED DRUG;

ARTICLE; CANCER IMMUNOTHERAPY; CARCINOGENESIS; CELL SURVIVAL; CLINICAL TRIAL (TOPIC); DISEASE COURSE; FEMALE; HUMAN; IMMUNE SYSTEM; IMMUNOLOGICAL TOLERANCE; IMMUNOREACTIVITY; INFLAMMATION; PREGNANCY; SIGNAL TRANSDUCTION; TUMOR INVASION; TUMOR MICROENVIRONMENT;

EID: 84941272751     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2015.00424     Document Type: Article

References (133)

1. Matzinger P. The danger model: a renewed sense of self. Science (2002) 296:301-5. doi:10.1126/science.1071059.
2. Enninga EA, Holtan SG, Creedon DJ, Dronca RS, Nevala WK, Ognjanovic S, et al. Immunomodulatory effects of sex hormones: requirements for pregnancy and relevance in melanoma. Mayo Clin Proc (2014) 89:520-35. doi:10.1016/j.mayocp.2014.01.006.
3. Holtan SG, Creedon DJ, Haluska P, Markovic SN. Cancer and pregnancy: parallels in growth, invasion, and immune modulation and implications for cancer therapeutic agents. Mayo Clin Proc (2009) 84:985-1000. doi:10.1016/S0025-6196(11)60669-1.
4. Nevala WK, Vachon CM, Leontovich AA, Scott CG, Thompson MA, Markovic SN. Evidence of systemic Th2-driven chronic inflammation in patients with metastatic melanoma. Clin Cancer Res (2009) 15:1931-9. doi:10.1158/1078-0432.CCR-08-1980.
5. Stewart TJ, Smyth MJ. Improving cancer immunotherapy by targeting tumor-induced immune suppression. Cancer Mets Rev (2011) 30:125-40. doi:10.1007/s10555-011-9280-5.
6. Marshall JA, Forster TH, Purdie DM, Lanagan CM, O'Connor LE, O'Rourke MG, et al. Immunological characteristics correlating with clinical response to immunotherapy in patients with advanced metastatic melanoma. Immunol Cell Biol (2006) 84:295-302. doi:10.1111/j.1440-1711.2006.01445.x.
7. Kawata A, Une Y, Hosokawa M, Uchino J, Kobayashi H. Tumor-infiltrating lymphocytes and prognosis of hepatocellular carcinoma. Jpn J Clin Oncol (1992) 22:256-63.
8. Lyle S, Salhany KE, Elder DE. TIA-1 positive tumor-infiltrating lymphocytes in nevi and melanomas. Mod Pathol (2000) 13:52-5. doi:10.1038/modpathol.3880009.
9. Prall F, Duhrkop T, Weirich V, Ostwald C, Lenz P, Nizze H, et al. Prognostic role of CD8+ tumor-infiltrating lymphocytes in stage III colorectal cancer with and without microsatellite instability. Hum Pathol (2004) 35:808-16. doi:10.1016/j.humpath.2004.01.022.
10. Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. New Engl J Med (2003) 348:203-13. doi:10.1056/NEJMoa020177.
11. Holtan SG, Mansfield AS, Creedon DJ, Nevala WK, Haluska P, Leontovich AA, et al. An organ system based approach to prognosis in advanced melanoma. Front Biosci (2012) 4:2823-33. doi:10.2741/E586.
12. Lowe DB, Storkus WJ. Chronic inflammation and immunologic-based constraints in malignant disease. Immunotherapy (2011) 3:1265-74. doi:10.2217/imt.11.113.
13. Kim T, Amaria RN, Spencer C, Reuben A, Cooper ZA, Wargo JA. Combining targeted therapy and immune checkpoint inhibitors in the treatment of metastatic melanoma. Cancer Biol Med (2014) 11:237-46. doi:10.7497/j.issn.2095-3941.2014.04.002.
14. Puzanov I, CM, Linette GP, Patel SP, Luke JJ, Sosman JA, et al. Phase 1 study of the BRAF inhibitor dabrafenib (D) with or without the MEK inhibitor trametinib (T) in combination with ipilimumab (Ipi) for V600E/K mutation-positive unresectable or metastatic melanoma (MM). J Clin Oncol (2014) 32:(5s Suppl) abstr 2511.
15. Starnes CO. Coley's toxins in perspective. Nature (1992) 357:11-2. doi:10.1038/357011a0.
16. Romagnani S. The Th1/Th2 paradigm. Immunol Today (1997) 18:263-6. doi:10.1016/S0167-5699(97)80019-9.
17. Smyth MJ, Crowe NY, Godfrey DI. NK cells and NKT cells collaborate in host protection from methylcholanthrene-induced fibrosarcoma. Int Immunol (2001) 13:459-63. doi:10.1093/intimm/13.4.459.
18. Shankaran V, Ikeda H, Bruce AT, White JM, Swanson PE, Old LJ, et al. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature (2001) 410:1107-11. doi:10.1038/35074122.
19. Landskron G, De la Fuente M, Thuwajit P, Thuwajit C, Hermoso MA. Chronic inflammation and cytokines in the tumor microenvironment. J Immunol Res (2014) 2014:149185. doi:10.1155/2014/149185.
20. Parker DC. T cell-dependent B cell activation. Annu Rev Immunol (1993) 11:331-60. doi:10.1146/annurev.iy.11.040193.001555.
21. Yokokawa J, Cereda V, Remondo C, Gulley JL, Arlen PM, Schlom J, et al. Enhanced functionality of CD4+CD25(high)FoxP3+ regulatory T cells in the peripheral blood of patients with prostate cancer. Clin Cancer Res (2008) 14:1032-40. doi:10.1158/1078-0432.CCR-07-2056.
22. Bates GJ, Fox SB, Han C, Leek RD, Garcia JF, Harris AL, et al. Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J Clin Oncol (2006) 24:5373-80. doi:10.1200/JCO.2006.05.9584.
23. Barbera-Guillem E, Nyhus JK, Wolford CC, Friece CR, Sampsel JW. Vascular endothelial growth factor secretion by tumor-infiltrating macrophages essentially supports tumor angiogenesis, and IgG immune complexes potentiate the process. Cancer Res (2002) 62:7042-9.
24. Lin EY, Li JF, Gnatovskiy L, Deng Y, Zhu L, Grzesik DA, et al. Macrophages regulate the angiogenic switch in a mouse model of breast cancer. Cancer Res (2006) 66:11238-46. doi:10.1158/0008-5472.CAN-06-1278.
25. Mantovani A, Sozzani S, Locati M, Allavena P, Sica A. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol (2002) 23:549-55. doi:10.1016/S1471-4906(02)02302-5.
26. Gabrilovich DI, Velders MP, Sotomayor EM, Kast WM. Mechanism of immune dysfunction in cancer mediated by immature Gr-1+ myeloid cells. J Immunol (2001) 166:5398-406. doi:10.4049/jimmunol.166.9.5398.
27. Bergers G, Brekken R, McMahon G, Vu TH, Itoh T, Tamaki K, et al. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol (2000) 2:737-44. doi:10.1038/35036374.
28. Yang L, DeBusk LM, Fukuda K, Fingleton B, Green-Jarvis B, Shyr Y, et al. Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell (2004) 6:409-21. doi:10.1016/j.ccr.2004.08.031.
29. Balkwill F, Charles KA, Mantovani A. Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell (2005) 7:211-7. doi:10.1016/j.ccr.2005.02.013.
30. David H. Rudolf Virchow and modern aspects of tumor pathology. Pathol Res Pract (1988) 183:356-64. doi:10.1016/S0344-0338(88)80138-9.
31. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell (2011) 144:646-74. doi:10.1016/j.cell.2011.02.013.
32. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature (2008) 454:436-44. doi:10.1038/nature07205.
33. Chin Y, Janseens J, Vandepitte J, Vandenbrande J, Opdebeek L, Raus J. Phenotypic analysis of tumor-infiltrating lymphocytes from human breast cancer. Anticancer Res (1992) 12:1463-6.
34. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science (2006) 313:1960-4. doi:10.1126/science.1129139.
35. Ino Y, Yamazaki-Itoh R, Shimada K, Iwasaki M, Kosuge T, Kanai Y, et al. Immune cell infiltration as an indicator of the immune microenvironment of pancreatic cancer. Br J Cancer (2013) 108:914-23. doi:10.1038/bjc.2013.32.
36. Knol AC, Nguyen JM, Pandolfino MC, Quereux G, Brocard A, Peuvrel L, et al. Tissue biomarkers in melanoma patients treated with TIL. PLoS One (2012) 7:e48729. doi:10.1371/journal.pone.0048729.
37. Kohrt HE, Nouri N, Nowels K, Johnson D, Holmes S, Lee PP. Profile of immune cells in axillary lymph nodes predicts disease-free survival in breast cancer. PLoS Med (2005) 2:e284. doi:10.1371/journal.pmed.0020284.
38. Cogswell PC, Guttridge DC, Funkhouser WK, Baldwin AS Jr. Selective activation of NF-kappa B subunits in human breast cancer: potential roles for NF-kappa B2/p52 and for Bcl-3. Oncogene (2000) 19:1123-31. doi:10.1038/sj.onc.1203412.
39. Houldsworth J, Mathew S, Rao PH, Dyomina K, Louie DC, Parsa N, et al. REL proto-oncogene is frequently amplified in extranodal diffuse large cell lymphoma. Blood (1996) 87:25-9.
40. Lu D, Thompson JD, Gorski GK, Rice NR, Mayer MG, Yunis JJ. Alterations at the rel locus in human lymphoma. Oncogene (1991) 6:1235-41.
41. Uffort DG, Grimm EA, Ellerhorst JA. NF-kappaB mediates mitogen-activated protein kinase pathway-dependent iNOS expression in human melanoma. J Invest Dermatol (2009) 129:148-54. doi:10.1038/jid.2008.205.
42. Keates S, Hitti YS, Upton M, Kelly CP. Helicobacter pylori infection activates NF-kappa B in gastric epithelial cells. Gastroenterology (1997) 113:1099-109. doi:10.1053/gast.1997.v113.pm9322504.
43. Kim H, Lim JW, Kim KH. Helicobacter pylori-induced expression of interleukin-8 and cyclooxygenase-2 in AGS gastric epithelial cells: mediation by nuclear factor-kappaB. Scand J Gastroenterol (2001) 36:706-16. doi:10.1080/003655201300191969.
44. Bosch FX, Ribes J, Borras J. Epidemiology of primary liver cancer. Semin Liver Dis (1999) 19:271-85. doi:10.1055/s-2007-1007117.
45. Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. New Engl J Med (2003) 348:518-27. doi:10.1056/NEJMoa021641.
46. Curiel-Lewandrowski C, Nijsten T, Gomez ML, Hollestein LM, Atkins MB, Stern RS. Long-term use of nonsteroidal anti-inflammatory drugs decreases the risk of cutaneous melanoma: results of a United States case-control study. J Invest Dermatol (2011) 131:1460-8. doi:10.1038/jid.2011.58.
47. Topalian SL, Drake CG, Pardoll DM. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell (2015) 27:450-61. doi:10.1016/j.ccell.2015.03.001.
48. Scott AM, Wolchok JD, Old LJ. Antibody therapy of cancer. Nat Rev Cancer (2012) 12:278-87. doi:10.1038/nrc3236.
49. Chen YT, Scanlan MJ, Sahin U, Tureci O, Gure AO, Tsang S, et al. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Natl Acad Sci U S A (1997) 94:1914-8. doi:10.1073/pnas.94.5.1914.
50. Coulie PG, Brichard V, Van Pel A, Wolfel T, Schneider J, Traversari C, et al. A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med (1994) 180:35-42. doi:10.1084/jem.180.1.35.
51. Kawakami Y, Eliyahu S, Delgado CH, Robbins PF, Sakaguchi K, Appella E, et al. Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proc Natl Acad Sci U S A (1994) 91:6458-62. doi:10.1073/pnas.91.14.6458.
52. Segal NH, Parsons DW, Peggs KS, Velculescu V, Kinzler KW, Vogelstein B, et al. Epitope landscape in breast and colorectal cancer. Cancer Res (2008) 68:889-92. doi:10.1158/0008-5472.CAN-07-3095.
53. Barrett DM, Singh N, Porter DL, Grupp SA, June CH. Chimeric antigen receptor therapy for cancer. Annu Rev Med (2014) 65:333-47. doi:10.1146/annurev-med-060512-150254.
54. Trainor N, Pietak A, Smith T. Rethinking clinical delivery of adult stem cell therapies. Nat Biotechnol (2014) 32:729-35. doi:10.1038/nbt.2970.
55. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. New Engl J Med (2010) 363:711-23. doi:10.1056/NEJMoa1003466.
56. Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. New Engl J Med (2013) 369:134-44. doi:10.1056/NEJMoa1305133.
57. Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, et al. Nivolumab plus ipilimumab in advanced melanoma. New Engl J Med (2013) 369:122-33. doi:10.1056/NEJMoa1302369.
58. Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. New Engl J Med (2012) 366:2455-65. doi:10.1056/NEJMoa1200694.
59. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. New Engl J Med (2001) 344:783-92. doi:10.1056/NEJM200103153441101.
60. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. New Engl J Med (2004) 350:2335-42. doi:10.1056/NEJMoa032691.
61. Maloney DG, Grillo-Lopez AJ, White CA, Bodkin D, Schilder RJ, Neidhart JA, et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood (1997) 90:2188-95.
62. KantoffPW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. New Engl J Med (2010) 363:411-22. doi:10.1056/NEJMoa1001294.
63. Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM, Leodolter S, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. New Engl J Med (2007) 356:1928-43. doi:10.1056/NEJMoa061760.
64. Paz-Ares LG, Biesma B, Heigener D, von Pawel J, Eisen T, Bennouna J, et al. Phase III, randomized, double-blind, placebo-controlled trial of gemcitabine/cisplatin alone or with sorafenib for the first-line treatment of advanced, nonsquamous non-small-cell lung cancer. J Clin Oncol (2012) 30:3084-92. doi:10.1200/JCO.2011.39.7646.
65. Kenter GG, Welters MJ, Valentijn AR, Lowik MJ, Berends-van der Meer DM, Vloon AP, et al. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. New Engl J Med (2009) 361:1838-47. doi:10.1056/NEJMoa0810097.
66. Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu P, Schwartzentruber DJ, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science (2002) 298:850-4. doi:10.1126/science.1076514.
67. Ishikawa H, Imano M, Shiraishi O, Yasuda A, Peng YF, Shinkai M, et al. Phase I clinical trial of vaccination with LY6K-derived peptide in patients with advanced gastric cancer. Gastric Cancer (2014) 17:173-80. doi:10.1007/s10120-013-0258-6.
68. Domschke C, Ge Y, Bernhardt I, Schott S, Keim S, Juenger S, et al. Long-term survival after adoptive bone marrow T cell therapy of advanced metastasized breast cancer: follow-up analysis of a clinical pilot trial. Cancer Immunol Immunother (2013) 62:1053-60. doi:10.1007/s00262-013-1414-x.
69. Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. New Engl J Med (2014) 371:1507-17. doi:10.1056/NEJMoa1407222.
70. Louis CU, Savoldo B, Dotti G, Pule M, Yvon E, Myers GD, et al. Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. Blood (2011) 118:6050-6. doi:10.1182/blood-2011-05-354449.
71. Raghupathy R. Th1-type immunity is incompatible with successful pregnancy. Immunol Today (1997) 18:478-82. doi:10.1016/S0167-5699(97)01127-4.
72. Lin H, Mosmann TR, Guilbert L, Tuntipopipat S, Wegmann TG. Synthesis of T helper 2-type cytokines at the maternal-fetal interface. J Immunol (1993) 151:4562-73.
73. Enninga EA, Holtan SG, Creedon DJ, Dronca RS, Nevala WK, Ognjanovic S, et al. Immunomodulatory effects of sex hormones: requirements for pregnancy and relevance in melanoma. Mayo Clin Proc (2014) 89:520-35. doi:10.1016/j.mayocp.2014.01.006.
74. Ferretti C, Bruni L, Dangles-Marie V, Pecking AP, Bellet D. Molecular circuits shared by placental and cancer cells, and their implications in the proliferative, invasive and migratory capacities of trophoblasts. Hum Reprod Update (2007) 13:121-41. doi:10.1093/humupd/dml048.
75. Peltier MR. Immunology of term and preterm labor. Reprod Biol Endocrinol (2003) 1:122. doi:10.1186/1477-7827-1-122.
76. Kwak JY, Beer AE, Kim SH, Mantouvalos HP. Immunopathology of the implantation site utilizing monoclonal antibodies to natural killer cells in women with recurrent pregnancy losses. Am J Reprod Immunol (1999) 41:91-8. doi:10.1111/j.1600-0897.1999.tb00080.x.
77. Girardi G, Yarilin D, Thurman JM, Holers VM, Salmon JE. Complement activation induces dysregulation of angiogenic factors and causes fetal rejection and growth restriction. J Exp Med (2006) 203:2165-75. doi:10.1084/jem.20061022.
78. Lutz M, Worschech A, Alb M, Gahn S, Bernhard L, Schwab M, et al. Boost and loss of immune responses against tumor-associated antigens in the course of pregnancy as a model for allogeneic immunotherapy. Blood (2014) 125:261-72. doi:10.1182/blood-2014-09-601302.
79. Lo YM, Corbetta N, Chamberlain PF, Rai V, Sargent IL, Redman CW, et al. Presence of fetal DNA in maternal plasma and serum. Lancet (1997) 350:485-7. doi:10.1016/S0140-6736(97)02174-0.
80. Poon LL, Leung TN, Lau TK, Lo YM. Presence of fetal RNA in maternal plasma. Clin Chem (2000) 46:1832-4.
81. Pertl B, Bianchi DW. Fetal DNA in maternal plasma: emerging clinical applications. Obstet Gynecol (2001) 98:483-90. doi:10.1016/S0029-7844(01)01195-4.
82. Chiu RW, Chan KC, Gao Y, Lau VY, Zheng W, Leung TY, et al. Noninvasive prenatal diagnosis of fetal chromosomal aneuploidy by massively parallel genomic sequencing of DNA in maternal plasma. Proc Natl Acad Sci U S A (2008) 105:20458-63. doi:10.1073/pnas.0810641105.
83. Phillippe M. Cell-free fetal DNA-a trigger for parturition. New Engl J Med (2014) 370:2534-6. doi:10.1056/NEJMcibr1404324.
84. Krieg AM, Yi AK, Matson S, Waldschmidt TJ, Bishop GA, Teasdale R, et al. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature (1995) 374:546-9. doi:10.1038/374546a0.
85. Zhang SY, Jouanguy E, Ugolini S, Smahi A, Elain G, Romero P, et al. TLR3 deficiency in patients with herpes simplex encephalitis. Science (2007) 317:1522-7. doi:10.1126/science.1139522.
86. O'Neill LA, Golenbock D, Bowie AG. The history of toll-like receptors-redefining innate immunity. Nat Rev Immunol (2013) 13:453-60. doi:10.1038/nri3446.
87. Ng EK, Tsui NB, Lau TK, Leung TN, Chiu RW, Panesar NS, et al. mRNA of placental origin is readily detectable in maternal plasma. Proc Natl Acad Sci U S A (2003) 100:4748-53. doi:10.1073/pnas.0637450100.
88. Litton C, Stone J, Eddleman K, Lee MJ. Noninvasive prenatal diagnosis: past, present, and future. Mt Sinai J Med (2009) 76:521-8. doi:10.1002/msj.20153.
89. Masuzaki H, Miura K, Yoshiura KI, Yoshimura S, Niikawa N, Ishimaru T. Detection of cell free placental DNA in maternal plasma: direct evidence from three cases of confined placental mosaicism. J Med Genet (2004) 41:289-92. doi:10.1136/jmg.2003.015784.
90. Levine RJ, Qian C, Leshane ES, Yu KF, England LJ, Schisterman EF, et al. Two-stage elevation of cell-free fetal DNA in maternal sera before onset of preeclampsia. Am J Obstet Gynecol (2004) 190:707-13. doi:10.1016/j.ajog.2003.12.019.
91. Crowley A, Martin C, Fitzpatrick P, Sheils O, O'Herlihy C, O'Leary JJ, et al. Free fetal DNA is not increased before 20 weeks in intrauterine growth restriction or pre-eclampsia. Prenat Diagn (2007) 27:174-9. doi:10.1002/pd.1645.
92. Sifakis S, Zaravinos A, Maiz N, Spandidos DA, Nicolaides KH. First-trimester maternal plasma cell-free fetal DNA and preeclampsia. Am J Obstet Gynecol (2009) 201(472):e471-7. doi:10.1016/j.ajog.2009.05.025.
93. Vora NL, Johnson KL, Basu S, Catalano PM, Hauguel-De Mouzon S, Bianchi DW. A multifactorial relationship exists between total circulating cell-free DNA levels and maternal BMI. Prenat Diagn (2012) 32:912-4. doi:10.1002/pd.3919.
94. Scharfe-Nugent A, Corr SC, Carpenter SB, Keogh L, Doyle B, Martin C, et al. TLR9 provokes inflammation in response to fetal DNA: mechanism for fetal loss in preterm birth and preeclampsia. J Immunol (2012) 188:5706-12. doi:10.4049/jimmunol.1103454.
95. Dabagh-Gorjani F, Anvari F, Zolghadri J, Kamali-Sarvestani E, Gharesi-Fard B. Differences in the expression of TLRs and inflammatory cytokines in pre-eclamptic compared with healthy pregnant women. Iran J Immunol (2014) 11:233-45. doi:lJlv11i4A2.
96. Minagawa M, Narita J, Tada T, Maruyama S, Shimizu T, Bannai M, et al. Mechanisms underlying immunologic states during pregnancy: possible association of the sympathetic nervous system. Cell Immunol (1999) 196:1-13. doi:10.1006/cimm.1999.1541.
97. Sugito Y, Sekizawa A, Farina A, Yukimoto Y, Saito H, Iwasaki M, et al. Relationship between severity of hyperemesis gravidarum and fetal DNA concentration in maternal plasma. Clin Chem (2003) 49:1667-9. doi:10.1373/49.10.1667.
98. Krug A, Towarowski A, Britsch S, Rothenfusser S, Hornung V, Bals R, et al. Toll-like receptor expression reveals CpG DNA as a unique microbial stimulus for plasmacytoid dendritic cells which synergizes with CD40 ligand to induce high amounts of IL-12. Eur J Immunol (2001) 31:3026-37. doi:10.1002/1521-4141(2001010)31:10<3026::AID-IMMU3026>3.0.CO;2-H.
99. Chan KC, Zhang J, Hui AB, Wong N, Lau TK, Leung TN, et al. Size distributions of maternal and fetal DNA in maternal plasma. Clin Chem (2004) 50:88-92. doi:10.1373/clinchem.2003.024893.
100. Jaenisch R, Bird A. Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals. Nat Genet (2003) 33(Suppl):245-54. doi:10.1038/ng1089.
101. Oligny LL. Human molecular embryogenesis: an overview. Pediatr Dev Pathol (2001) 4:324-43. doi:10.1007/s10024001-0033-2.
102. Poon LL, Leung TN, Lau TK, Chow KC, Lo YM. Differential DNA methylation between fetus and mother as a strategy for detecting fetal DNA in maternal plasma. Clin Chem (2002) 48:35-41.
103. Chim SS, Tong YK, Chiu RW, Lau TK, Leung TN, Chan LY, et al. Detection of the placental epigenetic signature of the maspin gene in maternal plasma. Proc Natl Acad Sci U S A (2005) 102:14753-8. doi:10.1073/pnas.0503335102.
104. Rothemund PW. Folding DNA to create nanoscale shapes and patterns. Nature (2006) 440:297-302. doi:10.1038/nature04586.
105. Leon SA, Shapiro B, SklaroffDM, Yaros MJ. Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res (1977) 37:646-50.
106. Mandel P, MP. Les acides nucleiques du plasma sanguine chez l'homme. C R Seances Soc Biol Fil (1948) 142:241-3.
107. Shapiro B, Chakrabarty M, Cohn EM, Leon SA. Determination of circulating DNA levels in patients with benign or malignant gastrointestinal disease. Cancer (1983) 51:2116-20. doi:10.1002/1097-0142(19830601)51:11<2116::AID-CNCR2820511127>3.0.CO;2-S.
108. Sozzi G, Conte D, Leon M, Ciricione R, Roz L, Ratcliffe C, et al. Quantification of free circulating DNA as a diagnostic marker in lung cancer. J Clin Oncol (2003) 21:3902-8. doi:10.1200/JCO.2003.02.006.
109. Zhong XY, Ladewig A, Schmid S, Wight E, Hahn S, Holzgreve W. Elevated level of cell-free plasma DNA is associated with breast cancer. Arch Gynecol Obstet (2007) 276:327-31. doi:10.1007/s00404-007-0345-1.
110. Diehl F, Li M, Dressman D, He Y, Shen D, Szabo S, et al. Detection and quantification of mutations in the plasma of patients with colorectal tumors. Proc Natl Acad Sci U S A (2005) 102:16368-73. doi:10.1073/pnas.0507904102.
111. Ng EK, Tsui NB, Lam NY, Chiu RW, Yu SC, Wong SC, et al. Presence of filterable and nonfilterable mRNA in the plasma of cancer patients and healthy individuals. Clin Chem (2002) 48:1212-7.
112. Jahr S, Hentze H, Englisch S, Hardt D, Fackelmayer FO, Hesch RD, et al. DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res (2001) 61:1659-65.
113. Anker P, Stroun M. Circulating DNA in plasma or serum. Medicina (Mex) (2000) 60:699-702.
114. Dawson SJ, Tsui DW, Murtaza M, Biggs H, Rueda OM, Chin SF, et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer. New Engl J Med (2013) 368:1199-209. doi:10.1056/NEJMoa1213261.
115. Lecomte T, Berger A, Zinzindohoue F, Micard S, Landi B, Blons H, et al. Detection of free-circulating tumor-associated DNA in plasma of colorectal cancer patients and its association with prognosis. Int J Cancer (2002) 100:542-8. doi:10.1002/ijc.10526.
116. Sozzi G, Conte D, Mariani L, Lo Vullo S, Roz L, Lombardo C, et al. Analysis of circulating tumor DNA in plasma at diagnosis and during follow-up of lung cancer patients. Cancer Res (2001) 61:4675-8.
117. Chan KC, Yeung SW, Lui WB, Rainer TH, Lo YM. Effects of preanalytical factors on the molecular size of cell-free DNA in blood. Clin Chem (2005) 51:781-4. doi:10.1373/clinchem.2004.046219.
118. Widschwendter M, Fiegl H, Egle D, Mueller-Holzner E, Spizzo G, Marth C, et al. Epigenetic stem cell signature in cancer. Nat Genet (2007) 39:157-8. doi:10.1038/ng1941.
119. Goessl C, Krause H, Muller M, Heicappell R, Schrader M, Sachsinger J, et al. Fluorescent methylation-specific polymerase chain reaction for DNA-based detection of prostate cancer in bodily fluids. Cancer Res (2000) 60:5941-5.
120. Sanchez-Cespedes M, Esteller M, Wu L, Nawroz-Danish H, Yoo GH, Koch WM, et al. Gene promoter hypermethylation in tumors and serum of head and neck cancer patients. Cancer Res (2000) 60:892-5.
121. Zhang L, Wang M, Wang W, Mo J. Incidence and prognostic value of multiple gene promoter methylations in gliomas. J Neurooncol (2014) 116:349-56. doi:10.1007/s11060-013-1301-5.
122. Jones PA, Baylin SB. The epigenomics of cancer. Cell (2007) 128:683-92. doi:10.1016/j.cell.2007.01.029.
123. Jahrsdorfer B, Wooldridge JE, Blackwell SE, Taylor CM, Griffith TS, Link BK, et al. Immunostimulatory oligodeoxynucleotides induce apoptosis of B cell chronic lymphocytic leukemia cells. J Leukoc Biol (2005) 77:378-87. doi:10.1189/jlb.0604373.
124. Carswell EA, Old LJ, Kassel RL, Green S, Fiore N, Williamson B. An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci U S A (1975) 72:3666-70. doi:10.1073/pnas.72.9.3666.
125. Pashenkov M, Goess G, Wagner C, Hormann M, Jandl T, Moser A, et al. Phase II trial of a toll-like receptor 9-activating oligonucleotide in patients with metastatic melanoma. J Clin Oncol (2006) 24:5716-24. doi:10.1200/JCO.2006.07.9129.
126. Wysocka M, Benoit BM, Newton S, Azzoni L, Montaner LJ, Rook AH. Enhancement of the host immune responses in cutaneous T-cell lymphoma by CpG oligodeoxynucleotides and IL-15. Blood (2004) 104:4142-9. doi:10.1182/blood-2004-03-1190.
127. Lamm DL, Thor DE, Harris SC, Reyna JA, Stogdill VD, Radwin HM. Bacillus Calmette-Guerin immunotherapy of superficial bladder cancer. J Urol (1980) 124:38-40.
128. Merz VW, Marth D, Kraft R, Ackermann DK, Zingg EJ, Studer UE. Analysis of early failures after intravesical instillation therapy with bacille Calmette-Guerin for carcinoma in situ of the bladder. Br J Urol (1995) 75:180-4. doi:10.1111/j.1464-410X.1995.tb07307.x.
129. Kaczanowska S, Joseph AM, Davila E. TLR agonists: our best frenemy in cancer immunotherapy. J Leukoc Biol (2013) 93:847-63. doi:10.1189/jlb.1012501.
130. Wolfle SJ, Strebovsky J, Bartz H, Sahr A, Arnold C, Kaiser C, et al. PD-L1 expression on tolerogenic APCs is controlled by STAT-3. Eur J Immunol (2011) 41:413-24. doi:10.1002/eji.201040979.
131. Pulko V, Liu X, Krco CJ, Harris KJ, Frigola X, Kwon ED, et al. TLR3-stimulated dendritic cells up-regulate B7-H1 expression and influence the magnitude of CD8 T cell responses to tumor vaccination. J Immunol (2009) 183:3634-41. doi:10.4049/jimmunol.0900974.
132. Enninga EA, Nevala WK, Creedon DJ, Markovic SN, Holtan SG. Fetal sex-based differences in maternal hormones, angiogenic factors, and immune mediators during pregnancy and the postpartum period. Am J Reprod Immunol (2014) 73:251-62. doi:10.1111/aji.12303.
133. Holmberg RC, Gindlesperger A, Stokes T, Lopez D, Hyman L, Freed M, et al. Akonni TruTip((R)) and Qiagen((R)) methods for extraction of fetal circulating DNA-evaluation by real-time and digital PCR. PLoS One (2013) 8:e73068. doi:10.1371/journal.pone.0073068.